Summary
88 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 42 USD is left as net profit.
- Revenue grew by 30% a year over the last 3 years.
- It earns 26 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $720.2M against $65.3M.
What to watch
- It missed profit estimates 4 times in the last 8 quarters.
- The price moves much more than the market (beta 1.82).
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 9.2 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 36% a year over 5 years. Over the last 3 years it grew by 30% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 13 USD
- Research and development 47 USD
- Sales and administration -2.1 USD
- Taxes and other -0.7 USD
- Net profit 42 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 42 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 19
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $35.5 is 36% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Collaboration Revenue 64%
- License Revenue 36%
By region
The company reports no revenue by region.
Collaboration Revenue brings in 64% of revenue. License Revenue grew fastest, by 22% a year.
Segments in detail